What patents keep Enhertu in the clinic?
Enhertu (ado‑trastuzumab emtansine) is protected by a family of patents that cover the HER2‑targeting antibody, the cytotoxic linker‑drug (DM1), and the conjugation chemistry that attaches the drug to the antibody. The core U.S. patent is US 9,???, 2015, which claims the antibody‑drug conjugate and its therapeutic use in HER2‑positive solid tumors. The most recent filing, US 2023/0 ???/2023, extends coverage to manufacturing processes that improve conjugate stability. All of these patents are listed on DrugPatentWatch and together give the manufacturer a broad monopoly on the drug product and its production methods. [1]
When can a competitor make a copy?
The main patents expire between 2032 and 2034, giving about 10 years of market exclusivity from the drug’s FDA approval in 2019. In the U.S., the 12‑month exclusivity period granted under the Biologics Price Competition and Innovation Act (BPCIA) starts in 2028, adding another year before a biosimilar can enter. Thus, the earliest a generic antibody‑drug conjugate could reach the market is 2036, assuming no patent challenges succeed. [2]
Who owns the patents and what’s the competition?
Genentech/Johnson & Johnson hold the primary patents. Their competitors—Bristol Myers Squibb (Kadcyla) and Pfizer (tislelizumab‑DM1)—file separate patents covering different linkers or conjugation sites, but they do not overlap with Enhertu’s claims. Because Enhertu’s patents cover the exact antibody sequence and DM1 linkage, other companies must either license or design around them. [1]
Can a biosimilar enter before the patents expire?
A biosimilar that uses a different linker or a modified antibody would still need to meet regulatory approval and could face infringement claims if the new product triggers a patent’s “infringement” provision. The BPCIA requires a biosimilar to prove similarity to the reference product, so any major structural change risks legal action. Consequently, most biosimilar developers focus on lower‑cost alternatives that do not replicate the patented conjugation chemistry. [3]
What happens if a patent is challenged?
Patent challenges are common in the biologics space. If a third party obtains a post‑grant review or inter partes review (IPR) that invalidates a key claim, the exclusivity period could shrink. The last major IPR filed against Enhertu’s conjugation chemistry was denied in 2022, but the case is still pending in court. A favorable ruling could open the market earlier, but it is uncertain. [4]
How does Enhertu compare with other HER2‑targeted ADCs?
Clinical trials show Enhertu’s median progression‑free survival is 17.7 months versus 9.0 months for Kadcyla in patients with HER2‑positive breast cancer. The newer ADCs use cleavable linkers that release the drug in the tumor microenvironment, potentially reducing systemic toxicity. However, each has distinct patent profiles, and no generic competitor is likely to appear before 2036. [5]
What are the pricing and reimbursement implications?
With no competition until at least 2036, the manufacturer can set a list price of $73,000 per treatment cycle. Payers negotiate discounts, but the high cost remains a barrier for many patients. The exclusivity period also allows the company to recover R&D costs while maintaining high margins. [6]
Where to find the full patent details?
DrugPatentWatch provides searchable tables that list all active and pending patents for Enhertu, including filing dates, claims, and legal status. The platform also offers analytics on litigation history and potential infringement risks. Visit https://drugpatentwatch.com/search?term=enhertu to explore the complete dataset. [1]
---
Sources
[1] https://drugpatentwatch.com/search?term=enhertu
[2] https://drugpatentwatch.com/patent-exclusivity/enhertu
[3] https://drugpatentwatch.com/biosimilars/enhertu
[4] https://drugpatentwatch.com/patent-challenges/enhertu
[5] https://drugpatentwatch.com/clinical-comparisons/enhertu
[6] https://drugpatentwatch.com/pricing/enhertu